


**Product Name** : Buloxibutid  
**Cat. No.** : PC-25932  
**CAS No.** : 477775-14-7  
**Molecular Formula** : C<sub>23</sub>H<sub>29</sub>N<sub>3</sub>O<sub>4</sub>S<sub>2</sub>  
**Molecular Weight** : 475.62  
**Target** : Angiotensin Receptor  
**Solubility** : 10 mM in DMSO



### Biological Activity

Buloxibutid (C21) is an orally available, selective, high-affinity angiotensin II type 2 receptor (AT2R) agonist with K<sub>i</sub> of 0.4 nM, >10,000-fold selective over AT1R.

Buloxibutid induces outgrowth of neurite cells, stimulates p42/p44(mapk), enhances in vivo duodenal alkaline secretion in Sprague-Dawley rats, and lowers the mean arterial blood pressure in anesthetized, spontaneously hypertensive rats.

Buloxibutid exerts a similar biological response as the endogenous peptide angiotensin II after selective activation of the AT(2) receptor.

Buloxibutid reduced vascular remodeling (reduced endothelial proliferation and thickening of the vascular wall) in vesselsof rat Sugen-hypoxia PH model.

Buloxibutid (C21) significantly inhibited AML progression and enhanced the efficacy of chemotherapy, particularly in relapsed AML models.

### References

Tornling G, et al. Int J Mol Sci. 2023 Apr 19;24(8):7478.

Steckelings UM, et al. Pharmacol Rev. 2022 Oct;74(4):1051-1135.

Yiqian Wan, et al. J Med Chem. 2004 Nov 18;47(24):5995-6008.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com